Professor Jon Wigginton: where we are standing in immunotherapy

Posted On 2015-07-06 11:25:04

Prof. Jon Wigginton was previously the Therapeutic Area Head, Immuno-Oncology, Early Clinical Research and Executive Director, Discovery Medicine-Clinical Oncology at Bristol-Myers Squibb (BMS), where he led the early clinical development of the BMS Immuno-Oncology portfolio includ-ing anti-PD-1 and anti-PD-L1. Prior to joining BMS, Dr. Wigginton was the Director of Clinical On-cology at Merck Research Laboratories, where he led early- and late-stage clinical development teams for small molecules and biologics. During his academic career, he held several positions at the National Cancer Institute Center for Cancer Research (NCI-CCR), including Head of Investiga-tional Biologics Section, Pediatric Oncology Branch. Dr. Wigginton is also past president of the In-ternational Society for the Biological Therapy of Cancer (now SITC). He is the author of over 50 manuscripts and reviews and is the recipient of multiple awards for scientific accomplishment from sources including the NIH, NCI, USPHS, iSBTc, ISICR, Children’s Cancer Foundation, Merck and BMS. Dr. Wigginton received his M.D. and B.S. in Biology, with distinction, from the University of Michigan.

During the 16th Annual Meeting of Chinese Society of Clinical Oncology (CSCO) held at Xiamen International Conference Center on October 28, 2013, we are honored to have an interview with Prof. Wigginton

Read More>>